6/18/2014 7:16:01 AM
While defending itself from US biotechnology giant, Pfizer, AstraZeneca (LSE: AZN) (NYSE: AZN.US) made an astonishing claim. The company claimed that it has the potential to nearly double its annual sales during the next 10 years.
Many City analysts expressed alarm at this forecast, calling it unreasonable. However, the company has a secret weapon — none other than CEO Pascal Soriot, the man who made the forecast in the first place.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by